Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Tuesday, soared 3.85% from the previous trading day, before settling in for the closing price of $1.3. Within the past 52 weeks, ZNTL’s price has moved between $1.01 and $5.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.89%. The company achieved an average annual earnings per share of 3.75%. With a float of $55.51 million, this company’s outstanding shares have now reached $71.95 million.
Let’s determine the extent of company efficiency that accounts for 166 employees. In terms of profitability, gross margin is 97.6%, operating margin of -789.32%, and the pretax margin is -834.36%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 22.85%, while institutional ownership is 76.55%. The most recent insider transaction that took place on Apr 30 ’25, was worth 29,373. In this transaction Director of this company bought 21,000 shares at a rate of $1.40, taking the stock ownership to the 281,192 shares. Before that another transaction happened on Feb 06 ’25, when Company’s Chief Medical Officer bought 20,000 for $2.28, making the entire transaction worth $45,656. This insider now owns 36,629 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 3.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.04% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 6.94 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -1.98 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Looking closely at Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL), its last 5-days average volume was 0.91 million, which is a drop from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 18.60%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 20.92%, which indicates a significant decrease from 25.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.23% in the past 14 days, which was higher than the 98.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3430, while its 200-day Moving Average is $2.4079. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $1.3983. Second resistance stands at $1.4467. The third major resistance level sits at $1.5033. If the price goes on to break the first support level at $1.2933, it is likely to go to the next support level at $1.2367. Should the price break the second support level, the third support level stands at $1.1883.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 97.14 million based on 71,952K outstanding shares. Right now, sales total 67,430 K and income totals -165,840 K. The company made 26,870 K in profit during its latest quarter, and -47,470 K in sales during its previous quarter.
